JP2017533945A5 - - Google Patents

Download PDF

Info

Publication number
JP2017533945A5
JP2017533945A5 JP2017526516A JP2017526516A JP2017533945A5 JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5 JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017526516 A JP2017526516 A JP 2017526516A JP 2017533945 A5 JP2017533945 A5 JP 2017533945A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
combination
sulbactam
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526516A
Other languages
English (en)
Japanese (ja)
Other versions
JP6764862B2 (ja
JP2017533945A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061076 external-priority patent/WO2016081452A1/en
Publication of JP2017533945A publication Critical patent/JP2017533945A/ja
Publication of JP2017533945A5 publication Critical patent/JP2017533945A5/ja
Application granted granted Critical
Publication of JP6764862B2 publication Critical patent/JP6764862B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017526516A 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法 Active JP6764862B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (3)

Publication Number Publication Date
JP2017533945A JP2017533945A (ja) 2017-11-16
JP2017533945A5 true JP2017533945A5 (OSRAM) 2018-12-20
JP6764862B2 JP6764862B2 (ja) 2020-10-07

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526516A Active JP6764862B2 (ja) 2014-11-17 2015-11-17 耐性細菌感染症の治療のための併用療法

Country Status (31)

Country Link
US (2) US9968593B2 (OSRAM)
EP (1) EP3221313B1 (OSRAM)
JP (1) JP6764862B2 (OSRAM)
KR (1) KR102542392B1 (OSRAM)
CN (1) CN107108624B (OSRAM)
AU (1) AU2015350128B2 (OSRAM)
BR (1) BR112017010132B1 (OSRAM)
CA (1) CA2966632C (OSRAM)
CY (1) CY1121384T1 (OSRAM)
DK (1) DK3221313T3 (OSRAM)
EA (1) EA033829B1 (OSRAM)
ES (1) ES2717776T3 (OSRAM)
HK (1) HK1244798B (OSRAM)
HR (1) HRP20190580T1 (OSRAM)
HU (1) HUE044061T2 (OSRAM)
IL (1) IL251979B (OSRAM)
LT (1) LT3221313T (OSRAM)
ME (1) ME03357B (OSRAM)
MX (1) MX2017006383A (OSRAM)
MY (1) MY196240A (OSRAM)
PH (1) PH12017500852B1 (OSRAM)
PL (1) PL3221313T3 (OSRAM)
PT (1) PT3221313T (OSRAM)
RS (1) RS58429B1 (OSRAM)
SG (1) SG11201703633TA (OSRAM)
SI (1) SI3221313T1 (OSRAM)
SM (1) SMT201900187T1 (OSRAM)
TR (1) TR201905233T4 (OSRAM)
TW (1) TWI690317B (OSRAM)
WO (1) WO2016081452A1 (OSRAM)
ZA (1) ZA201703245B (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900187T1 (it) 2014-11-17 2019-05-10 Entasis Therapeutics Ltd Terapia di combinazione per il trattamento di infezioni batteriche resistenti
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
PT3512851T (pt) * 2016-09-16 2022-10-11 Entasis Therapeutics Ltd Compostos inibidores de beta-lactamase
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA202190617A3 (ru) * 2017-02-08 2021-10-29 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
DK3630111T3 (en) 2017-05-08 2022-03-14 Entasis Therapeutics Inc Compounds and methods for treating bacterial infections
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
IL280770B2 (en) 2018-08-09 2024-05-01 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
BR112022018315A2 (pt) * 2020-04-02 2022-10-25 Glaxosmithkline Ip Dev Ltd Regime para tratar a infecção por neisseria gonorrhoeae com gepotidacina
CA3205756A1 (en) * 2021-01-20 2022-07-28 Entasis Therapeutics Limited Fixed dosage antibiotic compositions
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ274915A (en) 1993-12-29 1997-11-24 Pfizer N-(hetero)aryl methyl diazabicycloalkane derivatives
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
DK2231667T3 (da) * 2008-01-18 2013-12-16 Merck Sharp & Dohme Beta-lactamase-hæmmere
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2135959A1 (en) 2008-06-19 2009-12-23 Novexel Use of (1R,2S,5R) 1,6-Diazabicyclo [3,2,1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
KR101738210B1 (ko) 2011-07-26 2017-05-19 욱크하르트 리미티드 베타-락탐계 항생제, 술박탐 및 베타―락타마아제 저해제를 포함하는 약학 조성물
JP5808860B2 (ja) 2011-07-26 2015-11-10 ウォックハート リミテッド スルバクタム及びベータ−ラクタマーゼインヒビターを含む医薬組成物
PT2748165T (pt) 2011-08-27 2016-12-28 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona e sua utilização no tratamento de infeções bacterianas
KR101618424B1 (ko) 2011-08-30 2016-05-04 욱크하르트 리미티드 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도
EP3052497B1 (en) 2011-09-13 2017-06-28 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
AU2013237939A1 (en) 2012-03-30 2014-10-30 Cubist Pharmaceuticals, Inc. 1,3,4-oxadiazole and 1,3,4-thiadiazole beta-lactamase inhibitors
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
MX2014011825A (es) 2012-03-30 2015-02-20 Cubist Pharm Inc INHIBIDORES DE ISOXAZOL ß-LACTAMASA.
AR090539A1 (es) 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
PT2857401T (pt) 2012-05-30 2019-11-19 Meiji Seika Pharma Co Ltd Novo inibidor de β-lactamase e método para a produção do mesmo
AU2013308127B2 (en) 2012-08-25 2015-08-13 Wockhardt Limited 1,6- Diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
CN104768547A (zh) * 2012-09-03 2015-07-08 沃克哈特有限公司 抗菌组合物
BR112015018360B1 (pt) 2013-02-06 2022-03-22 Pfizer Anti-Infectives Ab Combinação de ceftazidima, ou um sal farmaceuticamente aceitável da mesma, e avibactam, ou um sal farmaceuticamente aceitável do mesmo para o tratamento de pneumonia nosocomial
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
SMT201900187T1 (it) 2014-11-17 2019-05-10 Entasis Therapeutics Ltd Terapia di combinazione per il trattamento di infezioni batteriche resistenti

Similar Documents

Publication Publication Date Title
JP2017533945A5 (OSRAM)
MY196240A (en) Combination Therapy for Treatment Of Resistant Bacterial Infections
MX387115B (es) Métodos para tratar la influenza.
WO2018115527A3 (en) Mers coronavirus vaccine
NZ616806A (en) Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
PH12016501577B1 (en) Monobactam organic compounds for the treatment of bacterial infections
UA107423C2 (en) Fluoro-pyridinone derivatives useful as antibacterial agents
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
ZA202002093B (en) Antibacterial compounds
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
SA517381678B1 (ar) مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي
RU2017145271A (ru) Терапевтическое средство для фиброза
IN2014MU00916A (OSRAM)
WO2015130547A8 (en) Bis-cyclic guanidine compound compositions, methods of use and treatment thereof
EA201890653A1 (ru) Композиция с противовирусным эффектом
MX2017013433A (es) Composiciones antibacterianas.
AR110913A1 (es) Compuesto aminoglucósido y su uso para prevenir o tratar enfermedades infecciosas
EA201890122A1 (ru) Применение 2-(5s-метил-2-оксо-4r-фенилпирролидин-1-ил)ацетамида в лечении судорог
MX379489B (es) Metodos para tratar la osteocondromatosis multiple (mo).
PH12016501215A1 (en) Azaindole derivative
JP2016003187A5 (OSRAM)
MX376923B (es) Composiciones antibacterianas.